Skip to main content


Pulmonary Hypertension

Pulmonary Hypertension
Jul 31, 2019

With the addition of Pulmonary Hypertension to our therapeutic areas of focus, Janssen has adopted Actelion’s unwavering commitment to creating a normal life for people with cardiopulmonary disease.

A rare, life-shortening disease, 1characterised by elevated pressure in the blood vessels of the lungs, 2pulmonary hypertension is difficult to diagnose. 3It’s estimated that just over 2,000 people in Australia have been diagnosed with PAH, 4but with prevalence data suggesting anywhere from 15 to 150 people per million population, 5the number living with the disease is likely to much higher.

Since the launch of PH-specific therapies, survival rates have improved – yet there is still much to be done.

Our commitment to this area has seen not only newer and more advanced therapies, but greater understanding of the best treatment regimens. As Actelion, a business unit of Janssen ANZ, we take this commitment to patients and healthcare professionals to heart – working tirelessly towards people having access to the best treatment options, and to creating a normal life for those living with pulmonary hypertension.

For more information about the programs and initiatives underway in the area of Pulmonary Hypertension, contact us


[1] Mak SM, Strickland N, Gopalan D. Complications of pulmonary hypertension: a pictorial review. Br J Radiol 2017;90:20160745.

[1] Galié N, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37:67-119.

[1] Vachiéry JL and Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012; 21:313-20.

[1] Department of Health, Drug Utilisation Sub-Committee (DUSC), 2015. Pulmonary Arterial Hypertension (PAH) medicines utilisation analysis. Available at: [Accessed March 2019].

[1] Strange G, et al. Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Heart Lung Circ, 2018;27(11):1368-1375